文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

通过整合IMRT与LDR前列腺近距离治疗剂量学确定联合模式剂量学约束并与毒性相关性分析

Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity.
PubMed 文献 · Adv Radiat Oncol · 2022-12-29

该研究对138例中高危前列腺癌患者,整合IMRT与103Pd基LDR近距离治疗计划,采用生物有效剂量和可变形图像配准计算尿道、膀胱、直肠联合剂量,并与泌尿生殖和胃肠道毒性进行相关性分析。结果显示3级毒性发生率低,作者据此提出尿道D10<200 Gy、直肠D2cc<60 Gy、膀胱D15<45 Gy作为联合治疗的初步剂量约束。

要点

  • 138例中高危前列腺癌患者接受IMRT联合103Pd LDR近距离治疗,采用BED和可变形图像配准整合剂量。
  • 前列腺BED D90为165.5±11.1 Gy,尿道BED D10为230.3±33.9 Gy,膀胱BED为35.2±11.0 Gy,直肠BED D2cc为85.6±24.3 Gy。
  • 作者提出尿道D10<200 Gy、直肠D2cc<60 Gy、膀胱D15<45 Gy作为联合模式的初步剂量约束。

核心结论

  • 作者成功将剂量整合技术应用于中高危前列腺癌患者样本,3级毒性发生率低,提示本研究中观察到的联合剂量是安全的,并提出初步剂量约束作为未来前瞻性研究和剂量递增的保守起点。

研究设计与样本

  • 对138例接受IMRT和103Pd基LDR近距离治疗的中高危前列腺癌患者,采用生物有效剂量和可变形图像配准整合治疗计划,比较尿道、膀胱和直肠联合剂量与泌尿生殖、胃肠道毒性,毒性分级间剂量差异用方差分析(α=0.05)评估。

主要发现

  • 138例患者中大多数发生0至2级泌尿生殖或胃肠道毒性,共记录6例3级毒性。
  • 前列腺BED D90(±1个标准差)为165.5±11.1 Gy,尿道BED D10为230.3±33.9 Gy,膀胱BED为35.2±11.0 Gy,直肠BED D2cc为85.6±24.3 Gy。
  • 膀胱平均BED、膀胱D15和直肠D50在不同毒性分级间存在显著剂量学差异,但各均值之间的差异未达统计学显著。

关键数值与推荐

  • 作者提出尿道D10<200 Gy、直肠D2cc<60 Gy、膀胱D15<45 Gy作为联合模式治疗的初步剂量约束。
  • 联合剂量约束采用平均危及器官剂量减去1个标准差作为保守推荐。

临床怎么用

  • 作者建议将尿道D10<200 Gy、直肠D2cc<60 Gy、膀胱D15<45 Gy作为初步剂量约束,作为未来前瞻性研究和剂量递增的保守起点。

局限性

  • 作者提出初步剂量约束作为保守起点,需在未来研究中前瞻性研究和递增。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intermediate- and high-risk prostate cancer patients undergoing combination external beam radiation therapy (EBRT) and low dose rate (LDR) brachytherapy have demonstrated increased genitourinary (GU) toxicity. We have previously demonstrated a method to combine EBRT and LDR dosimetry. In this work, we use this technique for a sample of patients with intermediate- and high-risk prostate cancer, correlate with clinical toxicity, and suggest preliminary summed organ-at-risk constraints for future investigation. METHODS AND MATERIALS: Intensity modulated EBRT and 103Pd-based LDR treatment plans were combined for 138 patients using biological effective dose (BED) and deformable image registration. GU and gastrointestinal (GI) toxicity were compared with combined dosimetry for the urethra, bladder, and rectum. Differences between doses in each toxicity grade were assessed by analysis of variance (α = 0.05). Combined dosimetric constraints are proposed using the mean organ-at-risk dose, subtracting 1 standard deviation for a conservative recommendation. RESULTS: The majority of our 138-patient cohort experienced grade 0 to 2 GU or GI toxicity. Six grade 3 toxicities were noted. Mean prostate BED D90 (± 1 standard deviation) was 165.5±11.1 Gy. Mean urethra BED D10 was 230.3±33.9 Gy. Mean bladder BED was 35.2±11.0 Gy. Mean rectum BED D2cc was 85.6±24.3 Gy. Significant dosimetric differences between toxicity grades were found for mean bladder BED, bladder D15, and rectum D50, but differences between individual means were not statistically significant. Given the low incidence of grade 3 GU and GI toxicity, we propose urethra D10 <200 Gy, rectum D2cc <60 Gy, and bladder D15 <45 Gy as preliminary dose constraints for combined modality therapy. CONCLUSIONS: We successfully applied our dose integration technique to a sample of patients with intermediate- and high-risk prostate cancer. Incidence of grade 3 toxicity was low, suggesting that combined doses observed in this study were safe. We suggest preliminary dose constraints as a conservative starting point to investigate and escalate prospectively in a future study.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Riegel AC, Nosrati JD, Sidiqi BU, et al. Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity. Adv Radiat Oncol. 2022. PMID: 36896208. doi:10.1016/j.adro.2022.101156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。